Search by PDB author

Potent, selective and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors
Descriptor:	(1S,2S,3S)-1-fluoranyl-2-[4-(5-fluoranylpyrimidin-2-yl)phenyl]-N-oxidanyl-3-phenyl-cyclopropane-1-carboxamide, HISTONE DEACETYLASE 4, SODIUM ION, ...
Authors:	Luckhurst, C.A, Breccia, P, Stott, A.J, Aziz, O, Birch, H, Burli, R.W, Hughes, S, Jarvis, R.E, Lamers, M, Leonard, P, Matthews, K.L, McAllister, G, Pollack, S, Saville-Stones, E, Wishart, G, Yates, D, Dominguez, C.
Deposit date:	2015-05-22
Release date:	2016-02-10
Last modified:	2024-01-10
Method:	X-RAY DIFFRACTION (2.65 Å)
Cite:	Potent, Selective, and Cns-Penetrant Tetrasubstituted Cyclopropane Class Iia Histone Deacetylase (Hdac) Inhibitors. Acs Med.Chem.Lett., 7, 2016

Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models
Descriptor:	2-morpholin-4-yl-6-[7-[(2~{R})-1-morpholin-4-ylpropan-2-yl]oxy-9~{H}-thioxanthen-4-yl]pyran-4-one, Phosphatidylinositol 3-kinase catalytic subunit type 3
Authors:	Leonard, P.M.
Deposit date:	2018-11-07
Release date:	2019-03-20
Last modified:	2024-01-24
Method:	X-RAY DIFFRACTION (2.09 Å)
Cite:	Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models. J.Med.Chem., 62, 2019

Structure-based exploration of selectivity for ATM inhibitors in Huntingtons disease
Descriptor:	4-morpholin-4-yl-6-[(2~{R})-2-(phenylmethyl)pyrrolidin-1-yl]-1~{H}-pyridin-2-one, Phosphatidylinositol 3-kinase catalytic subunit type 3
Authors:	Van de Poel, A, Leonard, P.M, Lamers, M.B.A.C.
Deposit date:	2020-04-06
Release date:	2021-04-14
Last modified:	2024-01-24
Method:	X-RAY DIFFRACTION (3.12 Å)
Cite:	Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease. J.Med.Chem., 64, 2021